AffaMed Therapeutics Announces Approval to Initiate a Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
AffaMed Technologies (AffaMed), a joint venture established between AffaMed Therapeutics and SIFI S.p.A., announced the completion of the first patient implantation in the Registrational Clinical Trial of its MINI WELL progressive Extended Depth-of-Focus (EDOF) IOL (MINI WELL), which was conducted in the EYE & ENT Hospital of Fudan University in Shanghai, China. This phacoemulsification cataract surgical procedure was successfully led by Professor Yi Lu, director of Ophthalmic Research Institute, and his study team.